Tumor recurrence and tumor-related mortality in endometrial cancer: Analysis in 276 patients.
| Autor: | Tejerizo-García A, Álvarez-Conejo C, Muñoz-Hernando L, Guillén-Gámez C, Seoane-Ruiz JM, Pérez-Sagaseta C, Jiménez-López JS; Department of Obstetrics and Gynecology, Hospital Universitario 12 de Octubre, Madrid, Spain. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Indian journal of cancer [Indian J Cancer] 2015 Oct-Dec; Vol. 52 (4), pp. 682-4. |
| DOI: | 10.4103/0019-509X.178425 |
| Abstrakt: | Background: In this manuscript, we assessed tumor recurrence and tumor-related mortality in a clinical series of endometrial cancer patients. Materials and Methods: A retrospective evaluation of 276 patients (mean age 64 years) with histologically confirmed endometrial cancer treated at a single hospital in Madrid (Spain) was conducted. The median follow-up was estimated using the inverse Kaplan-Meier method. Results: Salient findings were endometrioid carcinoma (84.8% of cases), grade G1 (48.9%) and stages IB (35.1%) and IC (23.2%). Myometrial infiltration >50% was documented in 31.2% of cases and lymphovascular space invasion in 11.9%. After surgery, 52.5% of patients were classified into the low risk group, 21.4% into the intermediate risk group and 26.1% into the high risk group. Tumor recurrence occurred in 14.5% of patients, with an estimated median follow-up of 45 months (95% confidence interval (CI): 41.2-48.8), locoregional recurrence in 42.5% and distant recurrences in 57.5%. Furthermore, 40% of tumor recurrences developed during the first year after primary treatment and 90% over the first 3 years of follow-up. The tumor-related mortality rate was 15.9%. The estimated median follow-up was 46 months (95% CI: 43.0-49.0). Furthermore, 5.07% of death because of tumor developed during the first year after primary treatment and 13.77% over the first 3 years of follow-up. Conclusion: The rates of tumor-related death and tumor recurrence in endometrial cancer patients are low, with the highest percentages occurring within 3 years of primary treatment. Most of the recurrences occur outside the pelvis. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|